Increasing cancer awareness and education in Hispanic communities
Official title: Outreach Core Activities
Run by H. Lee Moffitt Cancer Center and Research Institute · NCT05832177 · Data updated 2026-11-12
This study is trying to see if educational programs and community forums can help Hispanic communities learn more about cancer and reduce health disparities.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1200 (estimated) |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute Academic / other |
| Locations | 2 sites (Tampa, Florida and 1 other locations) |
| Status | Recruiting |
| Started | March 22, 2023 |
| Main results expected | July 2028 |
| Study ends | July 2028 |
| Registry record updated | February 20, 2026 |
| Trial ID | NCT05832177 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include Hispanic/Latino community members aged 18 and older who can communicate in Spanish or English.
✕Probably not a fit
Patients who do not meet the inclusion criteria or cannot participate in the educational programs may not benefit from this initiative.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Ponce Health Sciences University-Moffitt Cancer Center U54 Outreach Core aims to enhance cancer awareness and engagement in Hispanic/Latino communities. The initiative focuses on developing and delivering educational programs to reduce cancer health disparities, training community members as health promoters, and fostering research engagement. Activities include the Cancer CientoUno program and various community forums designed to facilitate discussions about cancer. The study seeks to empower community members through education and outreach efforts.
Why it matters
Potential benefit: If successful, this initiative could significantly improve cancer awareness and education among Hispanic/Latino populations, leading to better health outcomes.
How similar studies have gone: Other studies have shown success in community-based cancer education programs targeting minority populations, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Any health status * Able to speak, read and write Spanish or English (some events are in Spanish, some are in English) * \[Cancer 101 Online Training Program, Lunch and Learn podcast, and Stakeholders Program only\]: Have access to the internet * Willing to complete the training modules and assessments \[Cancer 101 Online Training Program\] * Willing to complete registration, attendance logs, and evaluations, as applicable * \[Community Engagement Training Program, Research Corner only\]: be a researcher who received U54 funding in the proposed renewal period including Full, Pilot, and Developmental projects. * \[Stakeholders in the Community-based Training Program and Cancer 101 Stakeholders program only\]: nurses, community health educators, clinical social workers, physicians, psychologists, among other healthcare professionals Exclusion Criteria: * Does not meet inclusion criteria
Where it's running
-
Moffitt Cancer Center
Tampa, Florida, United States Recruiting -
Ponce Health Sciences University
Ponce, Puerto Rico Recruiting
Study contacts
- Principal investigator: Shannon Christy, PhD — Moffitt Cancer Center
- Study coordinator: Shannon Christy, PhD
- Email: Shannon.Christy@moffitt.org
- Phone: 813-745-8840
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melanoma treatment with immunotherapy guided by serial ctDNA testing
This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.
-
Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma
This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.
-
Dendritic Cell Vaccine with HER2-targeted Therapy or Nivolumab for Breast Cancer with Leptomeningeal Metastasis
This trial tests a dendritic cell vaccine added to trastuzumab for Her2-positive disease or to nivolumab for Her2-negative disease to see if it can be given safely to people with breast cancer that has spread to the leptomeninges.
-
See if SAVI Scout MD helps surgeons localize breast cancer more precisely
This study tests whether the SAVI Scout MD radar reflectors help surgeons find and remove breast cancer more accurately, potentially reducing the need for a second operation.
-
PIPAC with Mitomycin C for unresectable peritoneal cancer
This phase 1 study tests a breathy, pressurized chemotherapy method (PIPAC-MMC) to see if it is safe and tolerable for adults with unresectable peritoneal carcinomatosis from colorectal, appendiceal, or small bowel cancers.
-
High-dose testosterone followed by PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
This trial tests whether short-term high-dose testosterone followed by a PSMA-targeted radioligand (PSMA-617) can help men with metastatic castration-resistant prostate cancer that is progressing on castrate-level testosterone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.